Autres langues Atea Pharmaceuticals, Inc.

Actions

AVIR

US04683R1068

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 03/05/2024			Varia. 5j.	Varia. 1 janv.
3,96 ^USD	+3,39%		+6,74%	+29,84%

27/03	Atea Pharmaceuticals, Inc. Achève le recrutement des patients de l'étude mondiale de phase 3 SUNRISE-3 évaluant l'antiviral oral bemnifosbuvir pour COVID-19 chez les patients à haut risque	CI
28/02	Atea Pharmaceuticals, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024	29/04
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients	27/03
Atea Pharmaceuticals, Inc. Completes Patient Enrollment in Global Phase 3 Sunrise-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients	27/03
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	28/02
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024	21/02
Atea Pharmaceuticals Reports 'Positive' Results on Hepatitis C Virus, COVID Trials; Shares Jump After Hours	08/01
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19	08/01
Atea Pharmaceuticals, Inc. Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus and Significant Enrollment for Phase 3 SUNRISE-3 Trial for COVID-19	08/01
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01
Atea Pharmaceuticals Says Bemnifosbuvir, Ruzasvir Combination Results Show Promise to Treat Hepatitis C Virus	13/11
Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023	13/11
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update	08/11
Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences	08/11
Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023	02/11
Atea Pharmaceuticals, Inc. to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD the Liver Meeting 2023	02/11
Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023	01/11
Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference	06/09/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Atea Pharmaceuticals, Inc.

Actions

AVIR

US04683R1068

Autres langues

Filtres